scispace - formally typeset
A

Ashwin N. Ananthakrishnan

Researcher at Harvard University

Publications -  529
Citations -  30046

Ashwin N. Ananthakrishnan is an academic researcher from Harvard University. The author has contributed to research in topics: Inflammatory bowel disease & Ulcerative colitis. The author has an hindex of 70, co-authored 468 publications receiving 22807 citations. Previous affiliations of Ashwin N. Ananthakrishnan include Boston Children's Hospital & Indian Institute of Technology Madras.

Papers
More filters
Journal ArticleDOI

Clinical Activity and Quality of Life Indices Are Valid Across Ulcerative Colitis But Not Crohn's Disease Phenotypes.

TL;DR: The authors' data suggest good correlation between SCCAI and endoscopic disease activity in UC, particularly in left-sided disease, appear to be consistent across different disease phenotypes.
Journal ArticleDOI

Loss of Response to Anti-Tumor Necrosis Factor Alpha Therapy in Crohn's Disease Is Not Associated with Emergence of Novel Inflammatory Pathways.

TL;DR: In this paper, the authors examined the colonic gene expression differences between those with active inflammation in the setting of loss of response to TNFα-antagonist therapy (loss of responders) compared to anti-TNFα naive patients with active inflammatory and those on anti-tNF therapy in disease remission.
Journal ArticleDOI

Dietary Gluten Intake and Risk of Microscopic Colitis Among US Women without Celiac Disease: A Prospective Cohort Study.

TL;DR: Dairy gluten intake during adulthood was not associated with risk of microscopic colitis among women without celiac disease and the null association did not differ according to lymphocytic or collagenous subtypes.
Journal ArticleDOI

Racial Disparities in Inhospital Outcomes for Hepatocellular Carcinoma in the United States.

TL;DR: Among patients admitted for HCC-related hospitalizations, blacks were less likely to receive liver transplantation, hepatic resection, and ablation than whites and had higher inhospital mortality.
Journal ArticleDOI

Discordance Between Patient-Reported Outcomes and Mucosal Inflammation in Patients With Mild to Moderate Ulcerative Colitis.

TL;DR: In a post-hoc analysis of data from a phase 3 trial of adults with mild to moderate UC treated with mesalazine, absence of rectal bleeding is found to identify patients in endoscopic remission, however, many patients in remission still have increased stool frequency, indicating that it may not be a sensitive marker of disease activity in patients with mild-to- moderate UC.